HER2 Expression Should Be Routinely Evaluated in DCIS to Avoid Under or Overtreatment | Oncoscience

Oncoscience published this editorial in Volume 10, entitled, “HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!” by researchers from Breast Services, Guy’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, United Kingdom; Centre for Cancer Prevention, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom.
#openaccess #radiotherapy #breastcancer #biomarkers #radiation #cancerresearch #openscience #peerreview #journal #research #editorial

DOI - https://doi.org/10.18632/oncoscience.572 (PDF Download)

Corresponding author - Mangesh A. Thorat - m.thorat@qmul.ac.uk

Keywords - DCIS, HER2, prognostic biomarker, predictive biomarker, radiotherapy

About Oncoscience

Oncoscience is a traditional, peer-reviewed, bio-medical oncology research journal with FREE publication for authors and open-access for readers.

To learn more about Oncoscience, please visit https://www.oncoscience.us/ and connect with us:

Facebook - https://www.facebook.com/Oncoscience
Twitter - https://twitter.com/OncoscienceJrnl
Instagram - https://www.instagram.com/oncosciencejrnl/
YouTube - https://www.youtube.com/@OncoscienceJournal
LinkedIn - https://www.linkedin.com/company/oncoscience/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957